Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT03850574 is registered in ClinicalTrials.gov with Aptose Biosciences Inc. as lead sponsor.

NCT NCT03850574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03850574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
Aptose Biosciences Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 11, 2019
Completion date
April 30, 2027
Enrollment
240 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, leukemia, myeloid, acute, myelodysplastic syndrome with excess blasts-2, refractory aml, relapsed adult aml